Results 81 to 90 of about 180,771 (310)

CD24 is a promising immunotherapeutic target for enhancing efficacy of third‐generation EGFR‐TKIs on EGFR‐mutated lung cancer

open access: yesCancer Communications, EarlyView.
Abstract Background Third‐generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) show initial efficacy in EGFR‐mutated lung cancer, but residual disease persists. This study aimed to investigate cluster of differentiation 24 (CD24) as a translational immunotherapeutic target for enhancing third‐generation EGFR‐TKI efficacy.
Jiaqi Liang   +16 more
wiley   +1 more source

Emerging targets in human lymphoma: targeting the MYD88 mutation [PDF]

open access: yes, 2016
B cell neoplasms co-opt the molecular machinery of normal B cells for their survival. Technological advances in cancer genomics has significantly contributed to uncovering the root cause of aggressive lymphomas, revealing a previously unknown link ...
Horikawa, Keisuke   +2 more
core   +1 more source

Foundational Principles for the Quantitative Translation of T‐Cell Therapeutics for Hematologic Malignancies and Immunology

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
T‐cell engaging antibodies (TCEs) and chimeric antigen receptor (CAR) T cells (CAR‐T cells) are among precision medicine therapies that have revolutionized the treatment of hematologic cancers. Their success in oncology has piqued interest in translating this promise into additional indications, such as autoimmune disorders.
Peter Ashcroft   +6 more
wiley   +1 more source

Latent membrane protein 1 (LMP1) expression in Hodgkin lymphoma and its correlation with clinical and histologic parameters

open access: yesWorld Journal of Surgical Oncology, 2017
Background Hodgkin lymphoma is one of the most prevalent lymphoproliferative disorders in Pakistan; however, no risk factors for this disease have yet to be established in our population.
Atif Ali Hashmi   +6 more
doaj   +1 more source

Primary extranodal non-Hodgkin lymphomas of the uterus and the breast: report of three cases [PDF]

open access: yes, 1995
The authors describe one case of a rare primitive non-Hodgkin lymphoma of the uterus, and two cases of primary non-Hodgkin lymphoma of the breast. Histologically, the uterine lymphoma, although clinically confined to the uterus, was a diffuse large cell ...
Amato, C.   +5 more
core   +1 more source

A Fast Path from Innovation to Safe and Effective Medicines

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Consistent progress in medicines development has allowed both for de novo treatment options and for the refinement of existing products that improve effectiveness or reduce harm. Nonetheless, unmet medical needs persist, particularly in rare diseases, pediatrics and underserved populations.
Peter Arlett   +11 more
wiley   +1 more source

Cardiovascular toxicity induced by TKIs in patients with chronic myeloid leukaemia: Are women and men different?

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1447-1454, April 2025.
This study analyzes 148 patients (66 women and 82 men) with chronic myeloid leukemia treated with tyrosine kinase inhibitors, focusing on cardiovascular adverse events. The risk assessment, performed using the HFA/ICOS score, reveals sex‐specific differences: venous thrombosis is more common in women, while arterial thrombosis predominates in men.
Cristina Madaudo   +10 more
wiley   +1 more source

Treatment-refractory non-Hodgkin lymphoma of the prostate: A case report and review of the literature

open access: yesUrology Case Reports, 2019
Non-Hodgkin lymphoma of the prostate is uncommon. Prostate specific antigen and transrectal ultrasound do not aid in diagnosis. Survival and treatment options are ultimately based on immune-histologic subtype and stage.
Alex Galante   +2 more
doaj   +1 more source

Four decades of heart–lung transplantation: Milestones and outcomes in advanced cardiorespiratory failure

open access: yesESC Heart Failure, EarlyView.
Abstract Aims Heart–lung transplantation (HLTx) remains a life‐saving intervention for patients with end‐stage cardiopulmonary failure. We retrospectively analysed long‐term HLTx outcomes at our centre to assess survival trends and evaluate the impact of evolving immunosuppressive, surgical and perioperative strategies.
L. Lily Rosenthal   +10 more
wiley   +1 more source

Primary non-hodgkin′s lymphoma of bone: Experience of a decade

open access: yesIndian Journal of Pathology and Microbiology, 2010
Objective: To study the prevalence and characterization of primary non Hodgkin′s lymphoma of bone in a major referral center of Pakistan. Methodology: All cases of primary non Hodgkin′s lymphoma of bone, diagnosed at a referral center in ...
Qureshi Asim   +3 more
doaj  

Home - About - Disclaimer - Privacy